» Articles » PMID: 27982283

Propofol Inhibits Invasion and Growth of Ovarian Cancer Cells Via Regulating MiR-9/NF-κB Signal

Overview
Date 2016 Dec 17
PMID 27982283
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Propofol is one of the most commonly used intravenous anesthetic agents during cancer resection surgery. A previous study has found that propofol can inhibit invasion and induce apoptosis of ovarian cancer cells. However, the underlying mechanisms are not known. miR-9 has been reported to be little expressed in ovarian cancer cells, which has been related to a poor prognosis in patients with ovarian cancer. Studies have also demonstrated that propofol could induce microRNAs expression and suppress NF-κB activation in some situations. In the present study, we assessed whether propofol inhibits invasion and induces apoptosis of ovarian cancer cells by miR-9/NF-κB signaling. Ovarian cancer ES-2 cells were transfected with anti-miR-9 or p65 cDNA or p65 siRNA for 24 h, after which the cells were treated with different concentrations of propofol (1, 5, and 10 μg/mL) for 24 h. Cell growth and apoptosis were detected using MTT assay and flow cytometry analysis. Cell migration and invasion were detected using Transwell and Wound-healing assay. Western blot and electrophoretic mobility shift assay were used to detect different protein expression and NF-κB activity. Propofol inhibited cell growth and invasion, and induced cell apoptosis in a dose-dependent manner, which was accompanied by miR-9 activation and NF-κB inactivation. Knockdown of miR-9 abrogated propofol-induced NF-κB activation and MMP-9 expression, reversed propofol-induced cell death and invasion of ES-2 cells. Knockdown of p65 inhibited NF-κB activation rescued the miR-9-induced down-regulation of MMP-9. In addition, overexpression of p65 by p65 cDNA transfection increased propofol-induced NF-κB activation and reversed propofol-induced down-regulation of MMP-9. Propofol upregulates miR-9 expression and inhibits NF-κB activation and its downstream MMP-9 expression, leading to the inhibition of cell growth and invasion of ES-2 cells.

Citing Articles

The synergistic mechanisms of propofol with cisplatin or doxorubicin in human ovarian cancer cells.

Sue S, Tseng W, Wu Z, Huang S, Chen J, Wu Z J Ovarian Res. 2024; 17(1):187.

PMID: 39272193 PMC: 11401282. DOI: 10.1186/s13048-024-01509-x.


The Inhibitory Effects of Propofol on Colorectal Cancer Progression through the NF-κB/HIF-1α Signaling Pathway.

Yao L, Zhai W, Jiang Z, He R, Xie W, Li Y Anticancer Agents Med Chem. 2024; 24(11):878-888.

PMID: 38571352 DOI: 10.2174/0118715206283884240326170501.


Does the Choice of Anaesthesia Affect Cancer? A Molecular Crosstalk between Theory and Practice.

Debel W, Ramadhan A, Vanpeteghem C, Forsyth R Cancers (Basel). 2023; 15(1).

PMID: 36612205 PMC: 9818147. DOI: 10.3390/cancers15010209.


General Anesthetics in Cancer Surgery: Can Anesthesiologists Help the Patient with More than a Safe Sleep.

Bonvini J Medicina (Kaunas). 2022; 58(9).

PMID: 36143832 PMC: 9503073. DOI: 10.3390/medicina58091156.


Sevoflurane Inhibits Metastasis in Hepatocellular Carcinoma by Inhibiting MiR-665-Induced Activation of the ERK/MMP Pathway.

Zhu X, Peng C, Peng Z, Chang R, Guo Q Cell Transplant. 2022; 31:9636897221104447.

PMID: 35699095 PMC: 9201366. DOI: 10.1177/09636897221104447.


References
1.
Lee J, Koo T, Yoon H, Jung H, Jin H, Lee K . Inhibition of NF-kappa B activation through targeting I kappa B kinase by celastrol, a quinone methide triterpenoid. Biochem Pharmacol. 2006; 72(10):1311-21. DOI: 10.1016/j.bcp.2006.08.014. View

2.
Husemann Y, Geigl J, Schubert F, Musiani P, Meyer M, Burghart E . Systemic spread is an early step in breast cancer. Cancer Cell. 2008; 13(1):58-68. DOI: 10.1016/j.ccr.2007.12.003. View

3.
Du Q, Xu Y, Zhang M, Yun P, He C . Propofol induces apoptosis and increases gemcitabine sensitivity in pancreatic cancer cells in vitro by inhibition of nuclear factor-κB activity. World J Gastroenterol. 2013; 19(33):5485-92. PMC: 3761101. DOI: 10.3748/wjg.v19.i33.5485. View

4.
Christopherson R, James K, Tableman M, Marshall P, Johnson F . Long-term survival after colon cancer surgery: a variation associated with choice of anesthesia. Anesth Analg. 2008; 107(1):325-32. DOI: 10.1213/ane.0b013e3181770f55. View

5.
Exadaktylos A, Buggy D, Moriarty D, Mascha E, Sessler D . Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis?. Anesthesiology. 2006; 105(4):660-4. PMC: 1615712. DOI: 10.1097/00000542-200610000-00008. View